University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

September 21, 2021

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

June 30, 2021

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.

May 28, 2021

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

May 11, 2021

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

May 05, 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

April 13, 2021

February 24, 2021

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

February 22, 2021

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

February 19, 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

January 28, 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

January 22, 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

January 13, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of multiple myeloma.

November 04, 2020

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

November 03, 2020

Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.

October 22, 2020

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

October 19, 2020

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

October 16, 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

October 13, 2020

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

October 12, 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

October 07, 2020

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.